Clinical Trials Sponsored by Vascular Scientific, LLC

Total 265 results

Ohio State University
Vascular Scientific, LLC

Completed

Dietary Supplementation in Heart Failure (R-DRINK)

Heart Failure

United States
Cagent Vascular LLC

Recruiting

Serranator Recoil Study

Peripheral Arterial Disease | Critical Limb Ischemia

United States, Germany
Vascular Solutions LLC

Completed

Safety and Efficacy Study Comparing Thrombin for Arterial Sealing

Hemostasis of Arterial Punctures

United States
Cagent Vascular LLC

Not yet recruiting

Serrantor OCT Study

Critical Limb Ischemia
Vascular Solutions LLC

Completed

Investigation of the Ringer Perfusion Balloon Catheter

Coronary Artery Perforation

United States
Vascular Solutions LLC

Completed

Investigation of the Ringer Perfusion Balloon Catheter (Ringer PTCA)

Coronary Stenosis

Canada, United States
Vascular Insights, LLC

Terminated

A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency (VICARES)

Venous Insufficiency

United States
Vascular Solutions LLC

Terminated

The BRILLIANT Study (BRILLIANT)

Varicose Veins

United States
Cagent Vascular LLC

Completed

The PRELUDE BTK Study

Peripheral Arterial Disease | Critical Limb Ischemia

New Zealand, Austria, Germany, Poland
Cagent Vascular LLC

Withdrawn

Serranator® Alto Post Market Clinical Follow Up (PMCF) Study

Peripheral Arterial Disease | Arteriovenous Graft | Arterio-venous Fistula
Cagent Vascular LLC

Completed

PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator DevicE (PRELUDE)

Peripheral Arterial Disease

New Zealand, Austria, Poland
Vascular Solutions LLC

Completed

Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins (RELIEVE)

Venous Insufficiency

United States
miR Scientific LLC

Active, not recruiting

Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico

Prostate Cancer

Puerto Rico
miR Scientific LLC

Active, not recruiting

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

Prostate Cancer

United States
miR Scientific LLC

Active, not recruiting

Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients

Bladder Cancer

United States
Berendo Scientific, LLC

Completed

SleepFlexTM Treatment of Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Multiple Myeloma

United States
Janssen Scientific Affairs, LLC

Completed

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

Hepatosplenic T-Cell Lymphoma

United States
Janssen Scientific Affairs, LLC

Terminated

An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease (ADAPT)

Inflammatory Bowel Diseases

United States, Canada
Janssen Scientific Affairs, LLC

Completed

Sustainable Early Episode Clinic Study (SEEC) (SEEC)

Schizophrenia | Schizoaffective Disorder

United States
Janssen Scientific Affairs, LLC

Completed

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis (AWARE)

Arthritis, Rheumatoid

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment

Suicidality

United States
Janssen Scientific Affairs, LLC

Completed

Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

Atrial Fibrillation

United States
Janssen Scientific Affairs, LLC

Withdrawn

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Pain | Chronic Low Back Pain | Chronic Back Pain | Osteoarthritis Pain In The Hip or Knee

United States
Janssen Scientific Affairs, LLC

Completed

Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

Healthy

United States
Janssen Scientific Affairs, LLC

Completed

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

HIV-1

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia

United States, Brazil, Mexico
Janssen Scientific Affairs, LLC

Terminated

Multiple Myeloma Patient Registry

Multiple Myeloma

United States
Janssen Scientific Affairs, LLC

Completed

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

HIV Infections | Pregnancy | HIV

United States, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability (REAAcT)

Prostate Cancer

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

Hepatitis C Virus

United States
Janssen Scientific Affairs, LLC

Completed

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Schizophrenia

United States, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Schizoaffective Disorder

United States, Ukraine, Bulgaria, India, Malaysia, Romania, South Africa, Philippines
Janssen Scientific Affairs, LLC

Completed

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Schizophrenia | Bipolar Disorder

United States
Janssen Scientific Affairs, LLC

Recruiting

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Crohn Disease | Colitis, Ulcerative

United States
Janssen Scientific Affairs, LLC

Active, not recruiting

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Psoriasis

United States, Australia, Ukraine, Belgium, Taiwan, Spain, Austria, Colombia, Israel, Portugal, Slovenia, Japan, Canada, Greece, Korea, Republic of, Argentina, Chile, Netherlands, Sweden, Slovakia, Czechia, Mexico
Janssen Scientific Affairs, LLC

Completed

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Multiple Myeloma

United States
Janssen Scientific Affairs, LLC

Available

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Multiple Myeloma
Janssen Scientific Affairs, LLC

Completed

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)

Crohn Disease

United States, Belgium, Korea, Republic of, Netherlands, Italy, United Kingdom, Canada, France, Australia, Bulgaria, Poland, Germany, Serbia, Czechia, Russian Federation, Spain, Brazil, Hungary
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
Janssen Scientific Affairs, LLC

Terminated

A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation (QUANTUM AF)

Atrial Fibrillation

United States
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
Janssen Scientific Affairs, LLC

Completed

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (FIRST)

Schizophrenia

United States
Janssen Scientific Affairs, LLC

Completed

Velcade (Bortezomib) Consolidation After Transplant (VCAT)

Multiple Myeloma

Australia, China, Korea, Republic of
Janssen Scientific Affairs, LLC

Completed

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Hypertension | Diabetes Mellitus, Type 2

United States, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (GALAXY)

Hepatitits C

United States
Palmaz Scientific
ClinLogix. LLC

Completed

Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study

Ischemic Heart Disease
Vascular Solutions LLC
Bright Research Partners; Teleflex

Completed

Chronic Total Occlusion Percutaneous Coronary Intervention Study (CTO-PCI)

Ischemic Heart Disease | Chronic Total Occlusion | Chronic Total Occlusion of Coronary Artery

United States
CirQuest Labs, LLC
Janssen Scientific Affairs, LLC

Unknown

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

Coronary Artery Disease | Heart Failure With Reduced Ejection Fraction

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (BROTHER)

Atrial Fibrillation

France

3

Subscribe